Cartesian Therapeutics, Inc. (RNAC)
Automate Your Wheel Strategy on RNAC
With Tiblio's Option Bot, you can configure your own wheel strategy including RNAC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNAC
- Rev/Share 1.3193
- Book/Share -0.8412
- PB -13.6236
- Debt/Equity -0.6456
- CurrentRatio 12.343
- ROIC -0.1328
- MktCap 297436278.0
- FreeCF/Share -1.5609
- PFCF -7.3566
- PE -7.7485
- Debt/Assets 0.0344
- DivYield 0
- ROE 1.1852
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | RNAC | BTIG Research | -- | Buy | -- | $42 | Dec. 19, 2024 |
News
Cartesian Therapeutics Announces New Employment Inducement Grants
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award …
Read More
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial
Read More
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March:
Read More
About Cartesian Therapeutics, Inc. (RNAC)
- IPO Date 2016-06-22
- Website https://selectabio.com
- Industry Biotechnology
- CEO Carsten Brunn
- Employees 66